Quantitative Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting Brain and Testis Penetration of Xenobiotic Compounds
Open Access
- 5 March 2008
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET)
- Vol. 36 (6), 995-1002
- https://doi.org/10.1124/dmd.107.019257
Abstract
The role of breast cancer resistance protein (BCRP/ABCG2) in limiting the brain and testis penetration of xenobiotic compounds in the blood-brain and -testis barriers was investigated using Bcrp–/– mice. Tissue/plasma concentration ratios in the brain (Kp,brain) and testis (Kp,testis) obtained under steady-state conditions were significantly increased in Bcrp–/– mice for PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine), N-hydroxyl PhIP, MeIQx (2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline), dantrolene, and prazosin. In addition, the Kp,brain of triamterene and the Kp,testis of 4′-hydroxyl PhIP were also significantly increased in Bcrp–/– mice. The effect of functional impairment of Bcrp on the brain uptake of PhIP, dantrolene, and daidzein in Bcrp–/– mice determined using in situ brain perfusion was weaker than that observed on the Kp values. In vitro transcellular transport experiments using cell lines expressing mouse Bcrp or P-glycoprotein (Mdr1a/Abcb1a) showed that, among the tested Bcrp substrates, PhIP, MeIQx, prazosin, and triamterene are common substrates of Bcrp and P-glycoprotein. The Kp values of common substrates exhibited a smaller increase both in the brain and testis of Bcrp–/– mice than expected from the in vitro Bcrp activities. The Bcrp-specific substrates were weak acids, whereas basic or neutral BCRP substrates were also P-glycoprotein substrates. These results suggest that BCRP limits the tissue penetration of xenobiotic compounds in the blood-brain and -testis barriers, but its in vivo importance is also modulated by P-glycoprotein activity.Keywords
This publication has 37 references indexed in Scilit:
- Involvement of Breast Cancer Resistance Protein (ABCG2) in the Biliary Excretion Mechanism of FluoroquinolonesPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2007
- Influence of breast cancer resistance protein (Abcg2) and p‐glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec®) across the mouse blood–brain barrierJournal of Neurochemistry, 2007
- The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in PatientsCancer Research, 2005
- Role of Breast Cancer Resistance Protein (Bcrp1/Abcg2) in the Extrusion of Glucuronide and Sulfate Conjugates from Enterocytes to Intestinal LumenMolecular Pharmacology, 2004
- Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pumpBlood, 2004
- XENOBIOTIC AND ENDOBIOTIC TRANSPORTER MRNA EXPRESSION IN THE BLOOD-TESTIS BARRIERDrug Metabolism and Disposition, 2004
- The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood–testis barrier and in primary testicular tumoursEuropean Journal Of Cancer, 2004
- An oncological view on the blood–testis barrierThe Lancet Oncology, 2002
- In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacinEuropean Journal of Pharmaceutical Sciences, 2000
- Development of anIn SituMouse Brain Perfusion Model and its Application tomdr1aP-Glycoprotein-Deficient MiceJournal of Cerebral Blood Flow & Metabolism, 2000